S&P 500   5,248.49
DOW   39,760.08
QQQ   444.85
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
7 Stocks That Will Drive the Weight Loss Drugs Market
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.85
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
7 Stocks That Will Drive the Weight Loss Drugs Market
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.85
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
7 Stocks That Will Drive the Weight Loss Drugs Market
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.85
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
7 Stocks That Will Drive the Weight Loss Drugs Market
NASDAQ:PRFX

PainReform (PRFX) Stock Price, News & Analysis

$1.77
-0.01 (-0.56%)
(As of 08:35 AM ET)
Today's Range
$1.77
$1.77
50-Day Range
$1.75
$2.31
52-Week Range
$1.77
$26.41
Volume
318 shs
Average Volume
20,374 shs
Market Capitalization
$3.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
PRFX stock logo

About PainReform Stock (NASDAQ:PRFX)

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. The company engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. It is currently conducting Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. The company was incorporated in 2007 and is based in Tel Aviv, Israel.

PRFX Stock Price History

PRFX Stock News Headlines

PainReform Provides Year-End Business Update
Major Elon Musk Crypto Leak Revealed
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
PainReform Ltd Ordinary Shares PRFX
PainReform (PRFX) Gets a Buy from Maxim Group
PRFX - PainReform Ltd.
PRFX Stock: The $2.7 Million Reason PainReform Is Up 100% Today
See More Headlines
Receive PRFX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PainReform and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
3/28/2024
Next Earnings (Estimated)
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PRFX
Fax
N/A
Employees
7
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.65 per share

Miscellaneous

Free Float
1,134,000
Market Cap
$3.08 million
Optionable
Not Optionable
Beta
0.53
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Dr. Ehud Geller Ph.D.
    Executive Chairman
  • Mr. Ilan Hadar M.B.A. (Age 55)
    CEO & CFO
    Comp: $404k
  • Dr. Sigal Aviel (Age 60)
    Chief Operating Officer
    Comp: $345k
  • Prof. Eli Hazum Ph.D.
    CTO & Director
  • Ms. Rita Keynan (Age 55)
    Vice President of Pharmaceutical Operations
    Comp: $302k
  • Dr. Stephen A. Cooper D.M.D Ph.D.
    Executive Vice President of Development

PRFX Stock Analysis - Frequently Asked Questions

How have PRFX shares performed in 2024?

PainReform's stock was trading at $2.75 at the beginning of 2024. Since then, PRFX shares have decreased by 35.3% and is now trading at $1.78.
View the best growth stocks for 2024 here
.

Are investors shorting PainReform?

PainReform saw a increase in short interest in March. As of March 15th, there was short interest totaling 13,900 shares, an increase of 504.3% from the February 29th total of 2,300 shares. Based on an average daily trading volume, of 23,400 shares, the days-to-cover ratio is currently 0.6 days. Currently, 1.0% of the company's stock are short sold.
View PainReform's Short Interest
.

When is PainReform's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our PRFX earnings forecast
.

How were PainReform's earnings last quarter?

PainReform Ltd. (NASDAQ:PRFX) announced its quarterly earnings data on Monday, November, 15th. The company reported ($1.80) earnings per share for the quarter, topping analysts' consensus estimates of ($4.30) by $2.50.

When did PainReform's stock split?

PainReform's stock reverse split on the morning of Monday, July 3rd 2023. The 1-10 reverse split was announced on Monday, July 3rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 3rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of PainReform own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PainReform investors own include Novartis (NVS), AbbVie (ABBV), American Airlines Group (AAL), Bank of America (BAC), Bristol-Myers Squibb (BMY), Clorox (CLX), Cisco Systems (CSCO), CVS Health (CVS), Delta Air Lines (DAL) and DocuSign (DOCU).

When did PainReform IPO?

PainReform (PRFX) raised $20 million in an initial public offering on Tuesday, September 1st 2020. The company issued 2,500,000 shares at a price of $8.00 per share. Maxim Group and Joseph Gunnar served as the underwriters for the IPO.

Who are PainReform's major shareholders?

PainReform's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (10.90%).

How do I buy shares of PainReform?

Shares of PRFX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PRFX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners